STUDIES ON FIXED DOSE COMBINATION OF IBRUTINIB AND QUERCETIN SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS IN HUMAN CANCER CELL LINES
Abstract
Ibrutinib (IB), irreversibly inhibits Bruton’s Tyrosine Kinase which plays a crucial role in the tumor microenvironment and Quercetin (QC) shown apoptosis induction, angiogenesis inhibition, and anti-proliferative action against several human carcinoma cells. The self nano-emulsifying drug delivery system (SNEDDS) is suitable for the loading of insolubilized oil-based compounds such as Ibrutinib and Quercetin. In the current study IB with QC was formulated into SNEDDS and cytotoxicity was determined by using Human malignant melanoma (A-375) and Human lung adenocarcinoma (A549) cell lines. The optimized loaded formula consisted of Castor oil, Kolliphor® RH 40, and PEG-600. The optimized formulation was evaluated for physical parameters and the results were satisfactory. For cytotoxicity studies MTT assay was conducted for these combinations, IC50 values were calculated for the tested compound. In A-549 adenocarcinoma cell line, the calculated IC50 values (μM) for the test compounds T1 (pure IB+QC) and T2 (IB+QC SNEDDS) were 70.34+ 0.8 µM and 85.46 + 0.93 µM at 24 h study, respectively. In A-375 cancer cell line, IC50 values for the compounds T1 and T2 were 59.52 + 0.87 µM and 88.43 + 1.03 µM for 24 h study, respectively. It was observed that the IC50 of IB-QC loaded SNEDDS was higher than pure drug combination and these enter the cells by active transport and induce cytotoxicity to the cells. The overall results from the studies suggest that IB-QC-loaded SNEDD provided synergistic effects, which could play a significant role in the percentage of cell death.
Keywords:
Ibrutinib, Quercetin, SNEDDS, Cell lines, CancerDOI
https://doi.org/10.25004/IJPSDR.2023.150610References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020;70(4):313.
Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41.
Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-38043.
Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. AAPS J. 2015;17(6):1327-40.
Hassan S, Peluso J, Chalhoub S, Idoux Gillet Y, Benkirane-Jessel N, Rochel N, Fuhrmann G, Ubeaud-Sequier G. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1. PLoS One. 2020;15(10):e0240676.
Muñoz J, Sarosiek S, Castillo JJ. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. Oncologist. 2023;28(4):309-318.
Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.
Xia S, Liu X, Cao X, Xu S. T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell Mol Immunol. 2020;17(10):1042-1052.
Salehi B, Machin L, Monzote L, Sharifi-Rad J, Ezzat SM, Salem MA, Merghany RM, El Mahdy NM, Kılıç CS, Sytar O, Sharifi-Rad M, Sharopov F, Martins N, Martorell M, Cho WC. Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health. ACS Omega. 2020;5(20):11849-11872.
Ye Q, Liu K, Shen Q, Li Q, Hao J, Han F, Jiang RW. Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids. Front Oncol. 2019;9:487.
Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. 2019;13:961.
Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002;62(4):1139-47.
Chen WH, Lu G, Chen X, Zhao XM, Bork P. OGEE v2: an update of the online gene essentiality database with special focus on differentially essential genes in human cancer cell lines. Nucleic Acids Res. 2017;45(D1):D940-D944.
Mohsin K, Long MA, Pouton CW. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci. 2009;98(10):3582-3595
Cerpnjak K, Zvonar A, Gašperlin M, Vrečer F. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs. Acta Pharm. 2013;63(4):427-445.
Mohsin K, Long MA, Pouton CW. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci. 2009;98(10):3582-3595.
Wu XW, Wang RF, Yuan M, Xu W, Yang XW. Dulbecco's modified eagle's medium and minimum essential medium--which one is more preferred for establishment of Caco-2 cell monolayer model used in evaluation of drug absorption?. Pharmazie. 2013;68(10):805-810.
Bahraminasab M, Arab S, Jahan A. Adaptation of MC3T3 cell line to Dulbecco's Modified Eagle's medium. Tissue Cell. 2020;64:101341.
Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer ChemotherPharmacol. 2007;59(6):749-757.
Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 1990;82(13):1113-8.
Ramadan MA, Shawkey AE, Rabeh MA, Abdellatif AO. Expression of P53, BAX, and BCL-2 in human malignant melanoma and squamous cell carcinoma cells after tea tree oil treatment in vitro. Cytotechnology. 2019;71(1):461-473.
Präbst K, Engelhardt H, Ringgeler S, Hübner H. Basic Colorimetric Proliferation Assays: MTT, WST, and Resazurin. Methods Mol Biol. 2017;1601:1-17.
Yu WX, Lu C, Wang B, Ren XY, Xu K. Effects of rapamycin on osteosarcoma cell proliferation and apoptosis by inducing autophagy. Eur Rev Med Pharmacol Sci. 2020;24(2):915-921.
Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713–2722.
How CW, Rasedee A, Manickam S, Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: Characterization, stability assessment and cytotoxicity. Colloids Surf. B Biointerfaces. 2013;112:393–399.
Rahman HS, Rasedee A, Othman HH, Chartr MS, Namvar F, Yeap SK, How CW. Acute Toxicity Study of Zerumbone-Loaded Nanostructured Lipid Carrier on BALB/c Mice Model. BioMed Res. Int. 2014;2014:563930.
Jain S, Garg T, Kushwah V, Thanki K, Agrawal AK, Dora CP. α-Tocopherol as functional excipient for resveratrol and coenzyme Q10-loaded SNEDDS for improved bioavailability and prophylaxis of breast cancer. Journal of drug targeting. 2017;25(6): 554–565.
Jain AK, Thanki K, Jain S. Novel self-nanoemulsifying formulation of quercetin: Implications of pro-oxidant activity on the anticancer efficacy. Nanomedicine: nanotechnology, biology, and medicine. 2014;10(5):959–969.
Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free radical biology & medicine. 2013;65:117–130.
Published
Abstract Display: 389 
PDF Downloads: 344 
